| Document |
Document Title |
|
WO/2022/017364A1 |
Disclosed are a sustained-release pharmaceutical formulation of a fused tricyclic γ-amino acid derivative and a preparation method therefor. The fused tricyclic γ-amino acid derivative is a compound represented by formula (I) or a ster...
|
|
WO/2022/016288A1 |
Disclosed herein are cannabinoid salt compounds formed by mixing an acidic cannabinoid compound with a base. According to embodiments of the present disclosure, the base is selected at least for having a low toxicity. Also disclosed are ...
|
|
WO/2022/020651A1 |
In some embodiments, the present disclosure provides amino acid compounds that are useful for producing products such as peptides. In some embodiments, the present disclosure provides peptides comprising residues of provided amino acids.
|
|
WO/2022/015677A2 |
Pre-texturing agents, etchants, and photoresist stripping agents may be formulated to include one or more branched surfactants, from one or more surfactant classes, such as derivatives of amino acids that have surface-active properties.
|
|
WO/2022/013706A1 |
The present invention relates to a process for the preparation of L-Glutamine of Formula (I). The present invention also relates to an improved process for the purification of L-Glutamine of Formula (I) having specific bulk density and H...
|
|
WO/2022/014395A1 |
This refining method involves crystallizing a compound that has at least one crystalline form, wherein: a specific infrared wavelength, at which a specific crystalline form precipitates from a solution obtained by dissolving the compound...
|
|
WO/2022/015606A1 |
The present disclosure pertains to branched surfactants for use in the formulation of detergents, foaming agents, emulsifiers, and degreasers. Some aspects of the invention include formulations suitable for cleaning and/or condition fabr...
|
|
WO/2022/016070A1 |
Compounds are provided having the following structure:, (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein a, b, c, d, G1, G2, L1, L2, R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8 and X are as...
|
|
WO/2022/014654A1 |
The present invention provides: a therapeutic and/or prophylactic agent for African swine fever (ASF) that contains 5-aminolevulinic acid (ALA), a derivative thereof or a salt of the same; and a therapeutic and/or prophylactic method for...
|
|
WO/2022/013439A1 |
The disclosure relates to novel lipidic compounds, method of manufacturing lipid nanoparticles (LNPs) containing thereof, lipid nanoparticles (LNPs) containing thereof, and the use of the LNPs for the delivery of nucleic acid. The lipidi...
|
|
WO/2022/015654A1 |
A zinc ascorbate glycinate co-salt having a formula of MC8H11NO8 and a suggested structure of: Formula (I). Where M is Ca, Mg, or Zn. The divalent metal ascorbate glycinate co-salt is formed as a powder having a metal content of about 8%...
|
|
WO/2022/010743A1 |
The present disclosure provides derivatives of amino acids that have branched alkyl structures and surface-active properties. The amino acid can be naturally-occurring or synthetic, or they may be obtained via a ring-opening reaction of ...
|
|
WO/2022/010744A1 |
The present disclosure provides derivatives of amino acids that have branched alkyl structures and surface-active properties. The amino acid can be naturally-occurring or synthetic, or they may be obtained via a ring-opening reaction of ...
|
|
WO/2022/009939A1 |
Provided are a method for acquiring a value relating to the triglyceride metabolic capacity of a subject within a shorter period of time compared to conventional nuclear medicine methods, and a test reagent and a test kit that are to be ...
|
|
WO/2022/005848A1 |
The present invention relates to the treatment of viral infection, and in particular to the use of an amount of a chelate of zinc and L-carnosineeffective to treat or to prevent infections associated with viruses in said human cells.
|
|
WO/2021/255525A1 |
The present invention relates to a process to prepare a crystalline co granule of MGDA-Nax, x being 2,5-3, containing a step of drying a crumbly phase composition containing on total weight of the composition (i) 70 - 87 wt% of organic c...
|
|
WO/2021/255180A1 |
The present invention relates to 2-aminoethanol, piperazine and L- lysine salts of Bempedoic acid and processes for the preparation thereof.
|
|
WO/2021/253305A1 |
A preparation method for DL-lysine, comprising the following steps: stirring L-lysine hydrochloride, acetic acid and water and increasing the temperature to 70-80°C, keeping the temperature and stirring for 1-6 hours, carrying out filte...
|
|
WO/2021/254671A1 |
The invention concerns new mono-ammonium compounds of formula (I) with surfactant properties and improved biodegradability. It concerns also new mixtures comprising such mono-ammonium compounds and di-ammonium compounds.
|
|
WO/2021/255387A1 |
The invention mainly concerns a method for producing aminocarboxylic acid having the following formula (I): NH3‐CH2‐(CH2)n‐COOH (I) in which n is an integer from 7 to 12, comprising the following steps: (i) reacting the unsaturated...
|
|
WO/2021/185072A9 |
Disclosed in the present invention are a crystal form of aromatic vinyl derivatives, and a preparation method therefor and the use thereof. Specifically disclosed in the present invention are crystal form A, crystal form B and crystal fo...
|
|
WO/2021/245503A1 |
This invention relates to a process of large scale manufacturing of 2-Amino-2-(difluoromethyl)-5-(2-propylpentanamido) pentanoic acid derivatives and their pharmaceutically acceptable salts, polymorphs, stereoisomers, enantiomers thereof...
|
|
WO/2021/244463A1 |
Provided in the present invention are/is a small-molecule inhibitor targeting an EB virus nuclear antigen protein and/or a pharmaceutical composition containing same, which can be used for the treatment of diseases caused by EBNA1 activi...
|
|
WO/2021/247537A1 |
The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates.
|
|
WO/2021/247531A1 |
The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates.
|
|
WO/2021/239687A1 |
The present disclosure provides novel Fe(lll)-complexes according to Chemical Formula (I): Chemical Formula (I) as well as enantiomers (and diastereomers) and solvates thereof. In Chemical Formula (I), Z is selected from O, NH and NR, wh...
|
|
WO/2021/236771A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-Ll or the PD-1/PD-Ll interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2021/234694A1 |
Lipid particles for nucleic acid delivery and clinical applications of same are provided. Accordingly there is provided a lipid particle comprising a cationic lipid encapsulating a nucleic acid sequence, wherein said nucleic acid sequenc...
|
|
WO/2021/227077A1 |
Provided are an amino acid composition and a method for producing an amino acid by means of energy radiation. The method comprises bringing a nanostructured catalyst, at least one nitrogen-containing source, at least one hydrogen-contain...
|
|
WO/2021/227436A1 |
The present invention belongs to the technical field of medicine synthesis, relates to an antifungal compound, and in particular relates to an antifungal compound, a synthesis method and the use thereof, wherein the antifungal compound i...
|
|
WO/2021/228037A1 |
Provided herein is formulations, systems and methods in which one or more compounds that inhibit AP2M1interaction with a protein motif utilized for trafficking of a viral protein are used to treat a broad range of viral infections. An ex...
|
|
WO/2021/226845A1 |
The present application provides a chelating agent, a cleaning agent and a method for preparing the chelating agent. The chelating agent has a general structural formula as shown in formula (I), wherein: R1, R2, R3 and R4 are alkyl group...
|
|
WO/2021/224217A1 |
The present invention relates to a new co-crystal of Ketoprofen, Lysine and Gabapentin, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
|
|
WO/2021/218930A1 |
Provided are a co-amorphous substance of celecoxib and pregabalin and a preparation method therefor. The co-amorphous substance, especially the co-amorphous substance, of which the molar ratio of celecoxib to pregabalin is 2:1, is stable...
|
|
WO/2021/216781A1 |
The present disclosure provides compounds of formula (I), (II), and (la): Methods of preparing these molecules and their use for treatment of Parkinson's Disease are described.
|
|
WO/2021/217006A1 |
(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis.
|
|
WO/2021/211436A1 |
The present application provides idebenone derivatives or analogues useful for treating a disease or disorder in a subject in need thereof. Pharmaceutical compositions comprising the compounds and methods of treating the disease or disor...
|
|
WO/2021/209486A1 |
The present invention relates to new herbicidally active pyrroline-2-ones according to general formula (I) or agrochemically acceptable salts thereof, and the use of these compounds for controlling weeds and weed grasses in plant crops.
|
|
WO/2021/204175A1 |
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid...
|
|
WO/2021/071033A9 |
The present invention relates to a method for preparing diethylamino hydroxybenzoyl hexyl benzoate and, specifically, to: a method for preparing diethylamino hydroxybenzoyl hexyl benzoate, which has a simple preparation process and can b...
|
|
WO/2021/202694A1 |
The present invention provides, in part, phenolic acid lipid compounds of Formula (I), and sub-formulas thereof, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mR...
|
|
WO/2021/184125A1 |
It is provided an anti-aging composition comprising at least one plant extract and a carrier, the at least one plant extract is at least one of Serenoa repens, Hypericum perforatum, Ilex paraguariensis, Ocimum tenuiflorum, Solidago virga...
|
|
WO/2021/189046A1 |
Compositions and method of reducing activity of a SARS-CoV-2 PLpro are provided. The methods typically include contacting a SARS-CoV-2 PLpro with an effective amount of a PLpro inhibitor compound to reduce the activity of the a SARS-CoV-...
|
|
WO/2021/180655A1 |
The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascul...
|
|
WO/2021/181159A1 |
The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombol...
|
|
WO/2021/183581A1 |
Pre-texturing agents, etchants, and photoresist stripping agents may be formulated to include one or more surfactants, from one or more surfactant classes, such as derivatives of amino acids that have surface-active properties.
|
|
WO/2021/183560A1 |
Agricultural products, such as pesticides, plant growth regulators, fungicides, herbicides, and insecticides, may be formulated to include one or more surfactants, from one or more surfactant classes, such as derivatives of amino acids t...
|
|
WO/2021/174475A1 |
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucousa.
|
|
WO/2021/175701A1 |
A process for making a complexing agent with an enantiomeric excess of at least 60%, wherein said process comprises the following steps: (a) reacting an aqueous slurry of alanine with an enantiomeric excess of at least 60% with formaldeh...
|
|
WO/2020/161362A9 |
The disclosure provides a process for the preparation of 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof, contemplated to be capable of modulating the activity of receptors, e.g., PPARs receptors.
|
